In this Healthed lecture, Associate Professor Samantha Hocking will discuss the evidence behind the new injectable, tirzepatide, a dual GIP/GLP-1 receptor agonist - how it can be initiated and used for ongoing diabetes management, as well as its safety and tolerability.See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.

In this Healthed lecture, Associate Professor Samantha Hocking will discuss the evidence behind the new injectable, tirzepatide, a dual GIP/GLP-1 receptor agonist - how it can be initiated and used for ongoing diabetes management, as well as its safety and tolerability. See omnystudio.com/listener for privacy information.

In this Healthed lecture, Associate Professor Samantha Hocking will discuss the evidence behind the new injectable, tirzepatide, a dual GIP/GLP-1 receptor agonist - how it can be initiated and used for ongoing diabetes management, as well as its safety and tolerability.See <a href="https://omnystudio.com/listener" rel="noopener noreferrer">omnystudio.com/listener</a> for privacy information.

Tirzepatide – What GPs Need to Know About Twincretin

Healthed's medical education channel features the latest high quality clinical interviews and lectures from leading experts in their field, offering health professionals a convenient new way to boost their knowledge.

Share Tirzepatide – What GPs Need to Know About Twincretin

Sign up to save your podcasts

Tirzepatide – What GPs Need to Know About Twincretin

Tirzepatide – What GPs Need to Know About Twincretin